SMAD5, affinity purified antibody, goat, 100 ug.
- Known as:
- SMAD5, antigenic enriched (anti-), caprine, 100 ug.
- Catalog number:
- GT15192-100
- Product Quantity:
- 1
- Category:
- -
- Supplier:
- Neuromi
- Gene target:
- SMAD5 affinity purified antibody goat 100 .
Related genes to: SMAD5, affinity purified antibody, goat, 100 ug.
- Gene:
- SMAD5 NIH gene
- Name:
- SMAD family member 5
- Previous symbol:
- MADH5
- Synonyms:
- Dwfc, JV5-1
- Chromosome:
- 5q31.1
- Locus Type:
- gene with protein product
- Date approved:
- 1997-07-01
- Date modifiied:
- 2016-10-25
- Gene:
- SMAD5-AS1 NIH gene
- Name:
- SMAD5 antisense RNA 1
- Previous symbol:
- SMAD5OS
- Synonyms:
- DAMS
- Chromosome:
- 5q31.1
- Locus Type:
- RNA, long non-coding
- Date approved:
- 2007-07-02
- Date modifiied:
- 2014-11-18
Related products to: SMAD5, affinity purified antibody, goat, 100 ug.
Related articles to: SMAD5, affinity purified antibody, goat, 100 ug.
- The aim of this study was to examine the expression profile, clinical significance, and potential diagnostic/prognostic value of the long non-coding RNA (lncRNA) SMAD5-AS1 in glioma. - Source: PubMed
Publication date: 2026/02/15
Ren JunqiShan XujunWu Hongrong - Re-epithelialization is an important physiological process for repairing skin barrier function during wound healing. It is primarily mediated by coordinated migration, proliferation, and differentiation of keratinocytes. Long noncoding RNAs (lncRNAs) are essential components of the noncoding genome and participate in various biological processes; however, their expression profiles and function in re-epithelialization during wound healing have not been established. - Source: PubMed
Publication date: 2024/02/26
Xiao YuntingZhang ChenyangLiu XiupingYang YongLandén Ning XuZhang ZhaoLi Dongqing - Nasopharyngeal carcinoma is a type of head and neck cancer with a high incidence in men. In the past decades, the survival rate of NPC has remained around 70%, but it often leads to treatment failure due to its distant metastasis or recurrence. The lncRNA-mRNA regulatory network has not been fully elucidated. We downloaded the NPC-related gene expression datasets GSE53819 and GSE12452 from the Gene Expression Omnibus database; GSE53819 included 18 NPC tissues and 18 normal tissues, and GSE12452 included 31 NPC tissues and 10 normal tissues. Weighted gene co-expression network analysis was performed on mRNA and lncRNA to screen out modules that were highly correlated with tumor progression. The two datasets were subjected to differential analysis after removing batch effects, and then Venn diagrams were used to screen for overlapping genes in the module genes and differential genes. The lncRNA-mRNA co-expression network was then constructed, and key mRNAs were identified by MCODE analysis and expression analysis. GSEA analysis and qRT-PCR were performed on key mRNAs. Through a series of analyses, we speculated that BTK, CD72, PTPN6, and VAV1 may be independent predictors of the prognosis of NPC patients.Taken together, our study provides potential candidate biomarkers for NPC diagnosis, prognosis, or precise treatment. - Source: PubMed
Publication date: 2022/07/26
Lu XuChen XingWang XinkeQing JingLi JiPan Yunyun - Long non-coding RNAs and microRNAs have recently attained much attention regarding their role in the development of B cell lineage as well as participation in the lymphomagenesis. These transcripts have a highly cell type specific signature which endows them the potential to be used as biomarkers for clinical situations. Aberrant expression of several non-coding RNAs has been linked with B cell malignancies and immune related disorders such as rheumatoid arthritis, systemic lupus erythematous, asthma and graft-versus-host disease. Moreover, these transcripts can alter response of immune system to infectious conditions. miR-7, miR-16-1, miR-15a, miR-150, miR-146a, miR-155, miR-212 and miR-132 are among microRNAs whose role in the development of B cell-associated disorders has been investigated. Similarly, SNHG14, MALAT1, CRNDE, AL133346.1, NEAT1, SMAD5-AS1, OR3A4 and some other long non-coding RNAs participate in this process. In the current review, we describe the role of non-coding RNAs in B cell malignancies. - Source: PubMed
Publication date: 2022/02/22
Ghafouri-Fard SoudehKhoshbakht TayyebehHussen Bashdar MahmudTaheri MohammadJamali Elena - Long non-coding RNAs (lncRNAs) have gained widespread attention in recent years as a key regulator of diverse biological processes, but the knowledge of the mechanisms by which they act is still very limited. Differentially expressed lncRNA SMAD5 antisense RNA 1 (SMAD5-AS1) in nasopharyngeal carcinoma (NPC) and normal samples shown by analyses were selected as the main subject, and then microRNA-195 (miR-195) was suggested to bind to SMAD5-AS1 and SMAD5. Therefore, the purpose of the present study was to investigate the effects of SMAD5-AS1/miR-195/SMAD5 on epithelial-mesenchymal transition (EMT) in NPC cells. High expression of SMAD5-AS1 and SMAD5 but low miR-195 expression was determined in NPC tissues and NPC cell lines by RT-qPCR and western blot analysis. SMAD5-AS1 could upregulate SMAD5 expression by competitively binding to miR-195 in NPC cells. Loss- and gain-of-function investigations were subsequently conducted in NPC cells (CNE-2 and CNE-1) to explore the role of SMAD5-AS, miR-195 and SMAD5 in NPC progression by assessing cellular biological functions and tumorigenic ability as well as determining the expression of EMT markers. Downregulation of SMAD5-AS1 or SMAD5 or overexpression of miR-195 led to inhibited NPC cell proliferation, invasion and migration and reversed EMT, enhanced apoptosis as well as restrained tumor growth . In conclusion, our findings indicate that silencing of lncRNA SMAD5-AS1 induces the downregulation of SMAD5 by miR-195, eventually repressing EMT in NPC. Hence, SMAD5-AS1 may represent a potential therapeutic target for NPC intervention. - Source: PubMed
Publication date: 2019/12/13
Li SiweiZhao BoZhao HaiyingShang CuiZhang ManXiong XiaoxiaPu JinjinKuang BohuaDeng Guangrui